Latest news

• Real-world data finds patients feel better on Entresto, says Novartis

  Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

• AZ gets US approval for Veltassa rival Lokelma

  AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. ... Lokelma (sodium zirconium cyclosilicate or ZS-9) has been cleared by the FDA as

• Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

  The company has a number of promising new cancer treatments, and has just received FDA approval for the delayed hyperkalaemia drug Lokelma.

• AZ finally gets EU nod for Veltassa rival Lokelma

  AstraZeneca has at long last won EU approval for Lokelma as an oral treatment for high potassium levels, more than a year after it was backed by the EMA’s Committee ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid

• Vifor wins European approval for Veltassa

  However, there’s potential competition on the horizon from AstraZeneca, which has a positive opinion the Committee for Medicinal Products for Human Use (CHMP) for its hyperkalaemia drug Lokelma (sodium zirconium ... This should have put Lokelma on